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Purified protein derivative (PPD) RT23-recalled T-cell receptor (TCR) V expression was studied in the
peripheral blood of 42 pulmonary tuberculosis patients and 44 healthy controls from southern India, a region
where tuberculosis is endemic. Forty-eight-hour whole-blood cultures in the presence or absence of PPD-RT23
were set up, and at the end of the culture period total RNA was extracted and cDNA was synthesized.
Expression of various TCR V families was assessed by using family-specific primers. PPD-specific expression
(usage) of TCR V families 4, 6, 8 to 12, and 14 was found in more controls than patients. Among the
responders (individuals who showed PPD-specific expression), endemic controls had significantly higher
responses than the patients had for TCR V families 2, 3, 7, 13, and 17. The majority of the patients did not
show usage of most of the TCR V families, and this was attributed to T-cell downregulation. A four-way nested
classification analysis revealed that TCR V family 1, 5, 9, 12, and 13 usage in the context of HLA class II
high-risk alleles (DRB1*1501, DRB1*08, and DQB1*0601) and Mycobacterium bovis BCG scar status were the
determining factors in susceptibility and resistance to tuberculosis. The healthier status of controls was
attributed to the wider usage of many TCR V families readily recalled by PPD, while the disease status of the
patients was attributed to TCR V downregulation and the resultant T-cell (memory cell?) unresponsiveness.
Host genetics (HLA status) and BCG vaccination (scar status) seem to play important roles in skewing the
immune response in adult susceptibility to pulmonary tuberculosis through TCR V usage.
Pulmonary tuberculosis, a major infectious disease in the
world, was declared a global emergency in 1993 (36). The
emergence of multi-drug-resistant Mycobacterium tuberculosis,
overcrowded, poor living conditions, and human immunodefi-
ciency virus coinfection have made this a serious health prob-
lem in India and other developing countries. The genetic hy-
pothesis that not all individuals infected with the tuberculosis
organism develop the disease requires further research (17,
21a). Tuberculosis is a paradigm of conflicts of several factors,
including genetics, immunopathology, epidemiology, and host
and pathogen diversity (11). Investigating the relative contri-
butions of these factors should lead to better intervention
strategies. A major constraint for such analyses is the lack of
availability of necessary readouts to evaluate these parameters
in the same cohort.
Studies in southern India have identified the high-risk alleles
HLA DR2 (DRB1*1501) and DQB1*0601 as predisposing
factors for sputum-positive, far-advanced pulmonary tubercu-
losis (4, 24, 27). Furthermore, expression of the Th2 cytokines
interleukin-10 (IL-10) and IL-4 is associated with Mycobacte-
rium bovis BCG scar-negative non-DR2 status in patients (7).
It has also been demonstrated that there is a spectrum of
immune reactivity (delayed-type hypersensitivity versus serum
antibodies) in hospital contacts and healthy individuals in
southern India, and this finding has been confirmed in other
countries where tuberculosis is highly endemic, such as Indo-
nesia and Brazil (3, 12, 22). However, we are unaware of the
epitope specificities of the responses.
Immunologists work under the premise that the epitopes
responsible for disease may be different from those affording
protection. Thus, the M. tuberculosis epitopes recognized by
patients might be different from those recognized by healthy
adult controls (immune individuals living in an endemic re-
gion). If this is true, the patients must differ from endemic
controls in terms of T-cell receptor (TCR) usage for mycobac-
terial antigens. We should then be in a position to recall this
memory in vitro by using a wider antigen, such as the purified
protein derivative (PPD) routinely used in skin tests to evalu-
ate sensitization or infection. By restricting the antigen we may
not recall global memory (with all the T cells recognizing
various epitopes of M. tuberculosis) and may not identify the
difference between patients and controls.
An important step in an adaptive immune response is rec-
ognition of the peptide major histocompatibility complex by
the TCR (8, 25, 37). The TCR repertoire of an individual is the
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outcome of thymic education in the context of the host major
histocompatibility complex. Certain TCR V families are
more common in individuals with certain HLA class I and class
II molecules (repertoire) (28), and HLA identical siblings are
more similar in terms of their TCR repertoires than HLA
nonidentical siblings (1). The repertoire is also influenced
postnatally by environmental exposure to specific and cross-
reacting antigens (23). The TCR repertoire of an individual is
the memory of experiences of the immune system, including
exposure to infectious and innocuous antigens. Thus, it should
be possible to identify the immunological memory for a par-
ticular antigen by studying TCR V expression in the presence
and absence of the antigen in vitro.
In this paper we describe the differences between endemic
controls and patients (disease status) in terms of PPD-recalled
TCR V expression. We found a correlation among HLA class
II high-risk alleles, BCG scar status, and PPD-specific TCR V
usage.
MATERIALS AND METHODS
Study population. (i) Pulmonary tuberculosis patients. A total of 42 adult
pulmonary tuberculosis patients, who were born and brought up in Madurai
District in southern India, were enrolled from a state-run public government
hospital in Singampunari, Madurai. Ethical clearance from the institutional
ethical committee was obtained for the study, and sampling was performed with
informed consent. The male/female ratio of the patients was 24:18, and the mean
age was 34.7  2.2 years. All the patients showed symptoms of pulmonary
tuberculosis with radiological lesions and a compatible clinical picture. The
patients were treated with ethambutol, isoniazid, rifampin, and pyrazinamide by
following the directly observed therapy protocol implemented in India. The
Blood samples were collected during weekly visits to the hospital, and at the time
of sampling patients had been treated for various lengths of time (see Table 3).
(ii) Healthy controls. Forty-four healthy endemic controls, all students and
staff of Madurai Kamaraj University living in Madurai District, were enrolled for
the study. None of these controls had any previous history or symptoms of
pulmonary tuberculosis. Their mean age was 26.6  0.76 years, and the male/
female ratio was 26:18.
HLA class II typing. HLA DRB1* and DQB1* alleles of the patients and
controls were studied by the PCR–sequence-specific oligoprobe method by using
primers and probes from the 11th International Histocompatibility Workshop
and Conference and the 12th International Histocompatibility Workshop and
Conference (2, 18).
Whole-blood cultures. Samples (3 to 5 ml) of peripheral blood were obtained
from the patients and controls in heparin vacutainers (455 051; Greiner, Frick-
enhausen, Germany) and were transferred to the laboratory. Whole-blood cul-
tures were set up on the same day (7). Briefly, 50 l of whole blood, diluted to
a volume of 200 l with RPMI 1640 medium (31870-025; Life Technologies,
Gibco-BRL, Gaithersburg, Md.) and supplemented with 2 mM glutamine (G-
1517; Sigma, St. Louis, Mo.), was cultured in quadruplicate for 48 h with or
without 20 U of PPD-RT23 in a CO2 incubator at 37°C in the presence of 5%
CO2 with 95% humidity. After 48 h, the cultures were harvested, and two of the
quadruplicate samples were pooled to obtain two aliquots, washed by centrifu-
gation, and frozen at 70°C in lysis buffer.
RNA extraction and cDNA synthesis. Total RNA was extracted from one
aliquot of the duplicate aliquots of each sample. RNA was extracted by a
single-step acid-phenol-chloroform extraction method (6), and all of the glass-
ware and all of the plastic ware were treated with 0.1% diethyl pyrocarbonate
(BDH Laboratory Supplies, Poole, United Kingdom). The RNA was primed
with 1 g of oligo(dT) primer (12- to 18-mer; 27-7858-02; Amersham Pharmacia
Biotech, Little Chalfont, Buckinghamshire, United Kingdom) at 65°C for 10 min
and cooled immediately on ice. cDNA was synthesized by using Moloney murine
leukemia virus reverse transcriptase (E70456Y; Amersham Pharmacia Biotech)
in a block heater at 37°C (9), diluted to a volume of 100 l with diethyl pyro-
carbonate water, and stored frozen.
PCR for TCR V genes. TCR V family-specific primers were synthesized by
using the primer sequences described by Hawes et al. (16) and Struyk et al. (32)
(Table 1). A total of 24 TCR V family-specific 5 primers, one TCR constant-
region (TCRC) 5 primer, and one constant-region 3 primer were synthesized by
Genosys, Pamisford, Cambridgeshire, United Kingdom. The 3 and 5 constant-
region primers were used to amplify the TCRC. The 3 TCRC primer was used
with one of the TCR V family-specific 5 primers to amplify and identify
expression of a given TCR V family. Five-microliter portions of the primer pairs
were predotted in 96-well plates, stored frozen at 70°C, and used within 1 week
of dotting. The PCR mixture (total volume, 20 l) was dispensed into each well.
Each reaction mixture contained 2 l of cDNA template, 0.5 U of Taq DNA
polymerase, each primer at a concentration of 0.2 M, each deoxynucleoside
triphosphate at a concentration of 0.4 mM, 4 mM MgCl2, and 1 PCR buffer.
Twenty-five PCRs were performed for each sample with a Hybaid thermal cycler
(Omnigene HBTR3CM; Hybaid Ltd., Middlesex, United Kingdom). The tem-
perature profile was as follows: initial denaturation at 95°C for 1 min; 35 cycles
of denaturation at 95°C for 1 min, annealing at 54.5°C for 1 min, and extension
at 72°C for 1.5 min; and then a final extension at 72°C for 10 min. The amplified
products were electrophoresed at 100 V for 30 min in a 1.5% agarose gel with
ethidium bromide. The gels were observed under UV illumination and docu-
mented by using a Kodak Digital Science gel documentation and analysis system
(Kodak ds EDAS 120; Eastman Kodak Company, Rochester, N.Y.). The TCR
V products were around 700 bp long, and the TCRC product was 300 bp long
(Fig. 1). The band intensities were measured in pixels by using the Kodak Digital
Science one-dimensional image analysis software.
Quality control measures. To avoid inter- and intraexperimental variations,
RNA extraction and cDNA synthesis for a batch of 10 samples (in the presence
and absence of PPD; 20 cDNAs) were performed simultaneously. The PCR,
electrophoresis, and measurement of the TCR V and TCRC band intensities
(in pixels) were all performed simultaneously. The TCRC amplicon served as an
amplification control. The net intensities of the TCR V bands in no-antigen
control and PPD-induced cultures were normalized to the TCRC band intensity
of each sample and expressed as percentages of the TCRC band intensity. The
antigen (PPD)-specific TCR V expression was obtained by subtracting the
percentage of the TCRC band intensity for the no-antigen control from the
percentage of the TCRC band intensity for the PPD-stimulated cultures. A
sample was considered positive for a TCR V family if the antigen-specific TCR
V expression was more than 5% of the TCRC band intensity.
Pilot experiments with whole-blood cultures in two control samples set up in
quadruplicate and stimulated with phytohemagglutinin (PHA), PPD, or nothing
revealed that PHA induced expression of all TCR V families except families 21,
TABLE 1. Primers used to amplify various TCR
V families and TCRCa
Primer Sequence
Forward primers
TCRBV1................5 AAGAGAGAGCAAAAGGAAACATTCTTGAAC 3
TCRBV2................5 GCTCCAAGGCCACATACGAGCAAGGCGTCG 3
TCRBV3................5 AAAATGAAAGAAAAAGGAGATATTCCTGAG 3
TCRBV4................5 CTGAGGCCACATATGAGAGTGGATTTGTCA 3
TCRBV5A.............5 ATACTTCAGTGAGACACAGAGAAAC3
TCRBV5B .............5TTCCCTAACTATAGCTCTGAGCTG3
TCRBV6................5CTCAGGTGTGATCCAATTTC3
TCRBV7................5 ATAAATGAAAGTGTGCCAAGTCGCTTCTCS 3
TCRBV8................5 AACGTTCCGATAGATGATTCAGGGATGCCC 3
TCRBV9................5 CATTATAAATGAAACAGTTCCAAATCGCTT 3
TCRBV10..............5 CTTATTCAGAAAGCAGAAATAATCAATGAG 3
TCRBV11..............5 TCCACAGAGAAGGGAGATCTTTCCTCTGAG 3
TCRBV12..............5 CTGAGATGTCACCAGACTGAGAACCACCGC 3
TCRBV13..............5CAAGGAGAAGTCCCCAAT3
TCRBV14..............5 GTGACTGATAAGGGAGATGTTCCTGAAGGG 3
TCRBV15..............5 GATATAAACAAAGGAGAGATCTCTGATGGA 3
TCRBV16..............5 CATGATAATCTTTATCGACGTGTTATGGGA 3
TCRBV17..............5GATATAAACAAAGGAGAGATCTCTGATGGA3
TCRBV18..............5 CATCTGTCTTCTGGGGGCAGGTCTCTCAAA 3
TCRBV19..............5GCACAAGAAGCGATTCTCATCTCAATGCCC3
TCRBV20..............5 TCTAATATTCATCAATGGCCAGCGACCCT 3
TCRBV21..............5 GATTCACAGTTGCCTAAGGAT 3
TCRBV22..............5 ATGCAGAGCGATAAAGGAAG 3
TCRBV23..............5 ATCTCAGAGAAGTCTGAAAT 3
TCRBV24..............5 GATTTTAACAATGAAGCAGA 3
5TCRBC...............5 CCGAGGTCGCTGTGTTTGAGCCAT 3
Reverse primer
3TCRBCb .............5CTCTTGACCATGGCCATC 3
a Data from references 16 and 32.
b 3TCRBC was used as the reverse primer in all 25 reactions along with a
TCR V family-specific or constant region 5 primer. There were two forward
primers for TCR V family 5 (TCRBV5A and TCRBV5B).
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23, and 24 in both donors. The failure with families 21, 23, and 24 was attributed
to PCR failure due to primers under the conditions used, and hence these three
TCR V families were not tested in further experiments. To test the reproduc-
ibility of the assay, whole-blood cultures of 10 samples were set up in quadru-
plicate in the presence of PPD, two cultures were pooled, and the two corre-
sponding cDNAs were synthesized. Expression of TCRC and TCR V families
was studied in both cDNAs, and the concordance in TCR V expression in the
two aliquots of the 10 samples was analyzed. Except for TCR V families 5, 11,
14, 18, and 19, all of the TCR V families showed more than 80% concordance.
The lower concordance in some of the TCR V families may have been due to
difficult primers under the conditions used. The quantitative expression data for
various TCR V families obtained with the two cDNA aliquots of the 10 samples
were concordant. Repeat assays for 11 TCR V families gave correlation coef-
ficients of 0.8 (P 	 0.003 to P 	 0.0001), and repeat assays for six TCR V
families gave correlation coefficients between 0.7 and 0.8 (P	 0.02 to P	 0.006).
In another set of experiments, PCRs with two different samples for TCRC and
V were performed twice on two different days. Although some of the data were
outside the 5% confidence interval, there was a good correlation between the
repeat assays (Fig. 2) (R 	 0.602, P 	 0.003; R 	 0.739, P 
 0.0001). The results
indicated that the methodological approach employed in this study was sufficient
to interpret the results obtained.
Statistical analyses. A paired t test, a Wilcoxon signed rank test, a Mann-
Whitney test, and a chi-square test were performed when necessary (29). Log-
linear analyses were performed by using BMPD statistical software (13).
RESULTS
Forty-four endemic controls and 42 pulmonary tuberculosis
patients were studied for TCR V expression in 48-h cultures
that were stimulated with PPD or without PPD (no-antigen
control). TCRC was expressed in all samples, and the expres-
sion was significantly higher in PPD-stimulated cultures than in
the no-antigen controls (P 
 0.0001). It is for this reason that
the expression data were normalized to the corresponding
TCRC data (see Materials and Methods). The TCR V fam-
ilies expressed in the no-antigen control cultures represented
the repertoire, and the difference between the expression in
the presence of the antigen and the expression in the absence
of the antigen represented the usage.
Comparison of TCR V expression in controls and patients.
The numbers of controls and patients expressing various TCR
V families in no-antigen controls were compared (Fig. 3A).
We found that 5 to 50% of the samples expressed at least one
of the TCR V families and that the number of individuals
expressing a particular TCR V family did not differ signifi-
cantly between controls and patients except for TCR V family
17 (P 	 0.048) (Fig. 3A). In the presence of PPD as many as
65% of the controls expressed selected TCR V families. Fur-
thermore, more controls than patients expressed many TCR
V families; eight TCR V families (TCR V families 4, 6, 8
to 12, and 14) were used by more controls than patients (Fig.
3B).
A quantitative analysis of the PPD-specific TCR V expres-
sion data in responders (the individuals who used a TCR V
family) was also performed (data not shown). The TCR V
expression levels were significantly higher in responding con-
trols than in responding patients for TCR V families 2, 3, 7,
13, and 17 (Mann-Whitney test: P	 0.05, P	 0.019, P	 0.027,
P 	 0.021, and P 	 0.037, respectively).
Thus, there could be two different mechanisms of TCR in-
volvement in protection or the disease process. First, PPD-
specific expression of TCR V families in more controls than
patients indicated that there was antigen-specific immune rec-
ognition of selected epitopes in protection. Second, the higher
level of selected TCR V family expression by controls indi-
FIG. 1. Agarose gels showing expression of various TCR V families in PHA- or PPD-stimulated, 48-h whole-blood cultures from a healthy
control. M, marker X-HaeIII.
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cated that there was adaptive immunity and immunological
memory in the controls. The absence of these phenomena in
patients may indicate that there was TCR V downregulation
due to antigenic load (25) and, presumably, restricted TCR V
usage in diseased patients.
The observation described above was further supported by a
comparison of TCR V expression in the absence and in the
presence of antigens in controls and patients. Figure 3 shows
that more controls (12 to 26 of the 44 controls) expressed TCR
V families 1, 5, 6, 9, 10, 11, 13, 14, and/or 18 in the presence
of antigen (PPD-specific expression) than in the absence of
antigen (1 to 12 of the 44 controls) (P 	 0.039, P 	 0.009, P 	
0.021, P 	 0.01, P 	 0.019, P 	 0.027, P 	 0.016, P 	 0.005,
and P 	 0.013, respectively). However, in patients only TCR
V family 2 showed significant usage (12 and 26 of 42 patients;
P 	 0.004).
Correlation among HLA high-risk allele status, BCG scar
status, and PPD-specific TCR V expression. Previous studies
in our laboratory showed that there is a high-risk association of
HLA DRB1*1501, DRB1*08, and DQB1*0601 with pulmo-
nary tuberculosis (24). Furthermore, cytokine IL-4 expression
and IL-10 expression were also associated with disease in non-
DRB1*02 patients who were not vaccinated with BCG (7). The
TCR V expression data presented here were therefore ana-
lyzed in the context of the BCG scar status and HLA high-risk
allele status.
Tables 2 and 3 show the control and patient samples studied,
HLA DRB1 and DQB1 allele data, BCG scar status, PPD-
FIG. 2. Concordance of repeat assays of TCR V expression in response to PHA in two different individuals (A and B). Whole-blood cultures
were set up in quadruplicate with 0.4 g of PHA and harvested after 48 h by pooling two wells. RNAs were extracted, cDNAs were synthesized
from both aliquots and pooled, and PCRs for TCR V families were performed by using TCR V family-specific primers twice on different days.
The net intensities for the repeat experiments (in pixels) are compared. The numbers near the data points indicate TCR V families. The
regression line, 95% confidence interval, and prediction interval are indicated. C, TCR constant region.
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specific expression of various TCR V families, and cytokine
expression data. The control and patient samples were divided
into four groups, based on high-risk allele status and BCG scar
status. The number of individuals responding (5% of TCRC
expressed) to a particular TCR V family in a group was
determined and defined as the number of responders. The
total number of TCR V families used by each individual was
also determined. Among the controls, the total number of
responders and the total number of TCR V families used
were more evenly distributed in all four groups (Table 2).
Nonetheless, among the patients, the majority of the respond-
ers (9 of 11 responders) expressing more than five TCR V
families were in the BCG scar-negative high-risk allele group
(Table 3). Most of the patients in the other three groups did
not respond; only 5 of 25 patients expressed more than five
TCR V families.
In order to determine whether chemotherapy has any effect
on TCR unresponsiveness in patients, we compared the num-
ber of TCR V families expressed in patients treated for 50
days (n 	 19) and the number of TCR V families expressed
in patients treated for 50 days (n 	 14). This analysis re-
vealed that there was recovery from TCR V unresponsiveness
in the BCG scar-negative HLA high-risk allele carrier patient
group following treatment. Of the 15 patients in this group, 7
were in the group that was treated for 50 days and expressed
five or fewer TCR V families, 3 were in the group that was
treated for 50 days and expressed more than five TCR V
families, none was in the group that was treated for 50 days
and expressed five or fewer TCR V families, and 5 were in the
group that was treated for 50 days and expressed more than
five TCR V families (P 	 0.0256, as determined by the Fi-
scher exact test). The cytokine data did not exhibit any rela-
tionship to the TCR V families expressed.
Nested classification analysis of HLA status, BCG status,
TCR V expression, and disease status. The interactions
among the four parameters in question (viz., disease status [D]
[healthy versus pulmonary tuberculosis], HLA status [H] [high-
risk allele carriers versus non-high-risk allele carriers], BCG
scar status [B] [positive versus negative], and TCR V family
usage status [T] [positive versus negative]) were assessed in a
nested classification analysis (13). The number of individuals
expressing a particular TCR V family in a group of controls
and patients was defined as the number of responders in Ta-
bles 2 and 3 and used for the analysis.
All possible log-linear models were considered and tested
for significance. Four models fit the observed data well (Table
4). TCR V families 1, 5, 9, 12, and 13 fit model 1 (TH, TD)
well (i.e., interaction of the TCR V families with HLA status
and with disease status). TCR V families 4, 6, 8, 10, 11, 14,
and 18 fit model 2 (TD, H, B) well, implying that there were
interactions between the TCR V families and disease status,
which were independent of HLA status and BCG scar status.
TCR V families 7 and 19 fit model 3 (TH, B, D) well (i.e.,
interaction between the TCR V families and HLA status,
independent of BCG status and disease status). TCR V fam-
ilies 2, 3, 15, 16, 17, 20, and 22 fit model 4 (T, H, BD) well (i.e.,
FIG. 3. TCR V responders in healthy controls and pulmonary tuberculosis patients. The data indicate the percentage of responders in each
TCR V family. (A) No-antigen control; (B) antigen-specific usage. P values were obtained based on a chi-square analysis with the Yates
correction.
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TCR V families were independent of HLA status, BCG sta-
tus, and disease status, although there were interactions
between BCG status and disease status). There was no cor-
relation between TCR V expression and other parameters,
including age, sex, caste, and cytokine expression.
DISCUSSION
In the present study we identified the BCG scar status- and
HLA class II high-risk allele status-dependent PPD-specific
expression of various TCR V families in patients and con-
trols. The controls used more TCR V families, while the
patients used only a few TCR V families. Furthermore, the
majority of the responders among patients belonged to the
BCG scar-negative HLA high-risk allele group.
In the present study carried out in an area in southern India
where tuberculosis is endemic, we identified expression of
many TCR V families in both controls and patients even in
the absence of antigen (repertoire). Exposure to various my-
cobacterial antigens in the environment, atypical mycobacteria,
and infection per se may have been the cause of this expres-
sion. The expression of TCR V families 4, 6, 8 to 12, and 14
in the presence of PPD in significantly more controls than
patients (Fig. 3) indicated that there was antigen-specific usage
of these TCR V families presumably involved in health status.
Most of the TCR usage (except usage of family 12) fit model 2
(i.e., TD interaction).
The lack of expression of many TCR V families and the
restricted usage in patients may have been the result of infec-
tion per se. The restricted TCR V usage in the peripheral
blood of the patients in the present study suggests that there is
a focused immune response to some selected epitopes of my-
cobacterial antigens or downregulation of TCR gene expres-
sion due to active suppression. Restricted TCR V expression
has been reported in multiple sclerosis, human immunodefi-
ciency virus infection, rheumatoid arthritis, and Epstein-Barr
virus infection (10, 14, 21, 33). AIDS patients that use one to
three TCR V families during primary infection deteriorate
rapidly, while other patients that use more TCR V families
deteriorate slowly (26). Patients with chronic hepatitis B show
underexpression of TCR V families 14 and 15 and expansion
of TCR V family 7 (5). Reactivation of PPD-specific Th1
lymphocytes with PPD resulted in a concentration-dependent
hyporesponsiveness due to an increase in apoptosis of , 
CD4, and  CD8 cells (30). It is possible that the cells
become unresponsive after signaling through their TCR (25).
Upon contact with antigen, cells may downregulate their TCR
and coreceptors. This may be a consequence of activation
under chronic stimulation conditions leading to anergy, a cel-
lular state in which a lymphocyte is alive but fails to exhibit
certain functional responses (25). This may be the mechanism
of failure of immune surveillance and the resultant disease
progression in chronic infections.
Limited TCR diversity with an antigen or infection can be
attributed to selection and expansion of certain antigen-spe-
cific T cells that become unresponsive in patients (15, 20). The
present study showed that this refractory status in patients was
determined by BCG scar status and HLA high-risk allele status
(Table 3). The downregulation observed might have been due
to the enormous amount of M. tuberculosis antigens available
in the system due to infection. This possibility was supported
by the observation that more TCR V families were used by
BCG scar-negative and HLA high-risk allele-positive patients
that were treated for 50 days than by patients that were
treated for 
50 days (P 	 0.0256). The perturbation in the
TCR repertoire and distribution thus seems to be a common
feature of various chronic infectious diseases (5, 10, 14, 28, 32,
33).
Investigators in the field of immunology are confronted with
dilemmas concerning the site and tissue used for sampling and
the antigens that are used. Cells and tissues obtained from the
focus of infection may be representative of the disease status
and may be the result of the localized immune response. On
the other hand, samples from the peripheral blood may indi-
cate the immune surveillance status of the individual. In many
previous studies on TCR V expression in various disease
states the workers have examined the TCR V repertoire at
the site of disease. In tuberculosis patients, Ohmen et al. iden-
tified selective expansion of TCR V family 8 in the pleural
fluid but not in the peripheral blood (19). In tuberculoid lep-
rosy patients, T cells bearing TCR V family 6 are overrepre-
sented in lesions but not in the peripheral blood (34, 35). M.
bovis hsp65 peptide-specific T-cell clones express more TCR
V families 5.1 and J 9 (15, 31). Previous studies of cytokine
expression in the peripheral blood of tuberculosis patients and
endemic controls have shown that there is PPD-specific en-
hancement or suppression of gamma interferon and IL-10 fol-
lowing 48 h of culture (7). The reason for the observed PPD-
recalled expression of many TCR V families in the peripheral
blood of more endemic controls than patients in the present
study can thus be attributed to the constant exposure to typical
TABLE 4. Best-fit log-linear models selected by nested
classification analyses of HLA status, BCG scar status,
disease status, and TCR V expression
Modela TCR V family
Likelihood ratio
Chi square Probability
1 (TH, TD) 1 15.04 0.1306
5 13.12 0.2171
9 13.79 0.1830
12 13.23 0.2110
13 20.88 0.0219
2 (TD, H, B) 4 12.52 0.2518
6 12.28 0.2666
8 12.07 0.2806
10 8.64 0.5661
11 6.62 0.4693
14 12.80 0.2350
18 16.51 0.0860
3 (TH, B, D) 7 8.65 0.5661
19 14.15 0.1663
4 (T, H, BD) 2 12.74 0.2384
3 14.58 0.1481
15 14.20 0.1641
16 9.16 0.5174
17 19.47 0.0347
20 7.60 0.6680
22 9.90 0.4496
a T, TCR V expression (positive or negative); H, high-risk HLA (DRB1*1501,
DRB1*08, DQB1*0601) status (positive or negative); B, BCG scar status (pos-
itive or negative); D, disease status (healthy or diseased). Best-fit log-linear
models were selected by using the BMPD statistical software (13).
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and atypical mycobacteria in the endemic environment and the
resultant memory. Such exposure has been suggested to be
responsible for the spectrum of immune reactivity in endemic
controls (3, 12, 22). The exposure and cross-reactivity might
have resulted in expansion and persistence of a defined T-cell
memory pool, performing immune surveillance. A broader an-
tigen, such as PPD, was thus capable of recalling this global
memory (all memory T cells directed towards various epitopes
of PPD shared with M. tuberculosis), leading to a better un-
derstanding of the factors involved in determining the prevail-
ing adaptive immune status, as indicated in the present study,
although we are unaware of the epitope specificity (since it was
not the purpose of the study). The use recombinant M. tuber-
culosis antigens and peptides in various subgroups as reported
in this paper may lead to identification of exact epitopes in-
volved in pathogenesis and resistance.
The present study demonstrated that it is possible to identify
PPD-recalled memory in the peripheral blood at the TCR V
usage level and account for the disease status (Table 4). Model
1 of the nested classification analysis revealed that usage of
PPD-specific TCR V families 1, 5, 9, 12, and 13 along with the
HLA class II high-risk alleles was involved in the disease pro-
cess, while model 2 suggested that TCR V families 4, 6, 8, 10,
11, 14, and 18 were also involved in the disease process, al-
though an HLA interaction could not be identified in the
cohort used. Model 4 revealed that BCG scar status interacted
with the disease status in the presence of TCR V 2, 3, 15, 16,
17, 20, and 22, as listed in Table 4. Thus, the disease status was
essentially linked to specific TCR V usage (models 1 and 2, 12
TCR V families) and HLA class II high-risk allele status
(model 1, five TCR V families). Previous studies have shown
that HLA-DR2 status, as well as HLA non-DR2, BCG scar-
negative status and IL-10 expression, are associated with pul-
monary tuberculosis (4, 7, 24). In the present study we identi-
fied a role for TCR V usage in tuberculosis susceptibility and
protection operating in the context of HLA high-risk allele
status and within the parameters of BCG vaccination and en-
vironmental exposure.
ACKNOWLEDGMENTS
Financial support from the Department of Biotechnology, Govern-
ment of India, New Delhi (grant BT/PRO281/Med/09/057/96), the
Commission of European Communities, Brussels, Belgium (fixed con-
tribution contract C/1-CT93-0079), The Wellcome Trust, London,
United Kingdom (grant 061237/Z/00/Z/HH/KO), and the Centre for
Scientific and Industrial Research, India (grant CSIR-SRF, Roll no.
112066992) is acknowledged.
We gratefully acknowledge the gift of PPD-RT23 from the BCG
vaccine laboratory, Guindy, Chennai, India. Permission from Di-
rector of Rural and Public Health, Government of Tamil Nadu
(H.Dis.104968/TB/1/97), to carry out this study is acknowledged.
REFERENCES
1. Akolkar, P., B. Gulwani-Akolkar, R. Pergolizzi, R. D. Bigler, and J. Silver.
1993. The influence of HLA genes on TCR V-segment frequencies and
expression levels in peripheral blood lymphocytes. J. Immunol. 150:4761–
4763.
2. Bignon, J. D., and M. A. Fernandez-Vina. 1997. Protocols of the 12th Inter-
national Histocompatibility Workshop for typing of HLA class II alleles by
DNA amplification by the polymerase chain reaction (PCR) and hybridiza-
tion with sequence specific oligonucleotide probes, p. 584–595. In D. Char-
ron (ed.), Genetic diversity of HLA—functional and medical implications,
vol. 1. EDK Publishers, Paris, France.
3. Bothamley, G. H., J. S. Beck, R. C. Potts, J. M. Grange, T. Kardjito, and J.
Ivanyi. 1992. Specificity of antibodies and tuberculin response after occupa-
tional exposure to tuberculosis. J. Infect. Dis. 166:182–186.
4. Brahmajothi, V., R. M. Pitchappan, V. N. Kakkanaiah, M. Sashidhar, K.
Rajaram, S. Ramu, K. Palanimurugan, C. N. Paramasivan, and R. Prab-
hakar. 1991. Association of pulmonary tuberculosis and HLA in south India.
Tubercle 72:123–132.
5. Chen, X., G. Cooksley, and G. Sing. 1998. Distinct patterns of T cell receptor
distribution of peripheral blood CD8 cells during different stages of chronic
infection with hepatitis B virus. Hum. Immunol. 59:199–211.
6. Chomczynski, P., and N. Sacchi. 1987. Single step method of RNA isolation
by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Bio-
chem. 162:156–159.
7. Dheenadhayalan, V., S. Shanmugalakshmi, S. Vani, P. Muthuveeralakshmi,
G. Arivarignan, A. D. Nageswari, and R. M. Pitchappan. 2001. Association
of interleukin-10 cytokine expression status with HLA non-DRB1*02 and
Mycobacterium bovis BCG scar-negative status in south Indian pulmonary
tuberculosis patients. Infect. Immun. 69:5635–5642.
8. Dustin, M. L., and A. S. Shaw. 1999. Costimulation: building an immuno-
logical synapse. Science 283:649–650.
9. Ehlers, S., and K. A. Smith. 1991. Differentiation of T cell like lymphokine
gene expression: the in vitro acquisition of T cell memory. J. Exp. Med.
173:25–36.
10. Elewaut, D., F. de Keyser, F. van den Bosch, G. Verbruggen, and E. M. Veys.
2000. Broadening of the T cell receptor spectrum among rheumatoid arthri-
tis synovial cell-lines in relation to disease duration. Clin. Exp. Rheumatol.
18:201–207.
11. Fine, P. E. M. 1995. Variation in protection by BCG: implication of and for
heterologous immunity. Lancet 346:1339–1345.
12. Fonseca, L. D., D. R. Biscaya, M. H. Saad, and F. M. Martins. 1992. The
spectrum of immune response to M. tuberculosis in healthy individuals.
Tuber. Lung Dis. 73:242.
13. Fox, J. 1985. Linear statistical model and related methods, p. 341–347. John
Wily & Sons, New York, N.Y.
14. Gorochov, G., A. U. Neumann, A. Kereveur, C. Parizot, T. Li, C. Katlama, M.
Karmochkine, G. Raguin, B. Autran, and P. Debre. 1998. Perturbation of
CD4 and CD8 T-cell repertoires during progression to AIDS and regu-
lation of the CD4 repertoire during antiviral therapy. Nat. Med. 4:215–221.
15. Hawes, G. E., L. Struyk, B. C. Godthelp, and P. J. van den Elsen. 1995.
Limited restriction in the TCR- V region usage of antigen-specific clones.
J. Immunol. 154:555–566.
16. Hawes, G. E., L. Struyk, and P. J. van den Elsen. 1993. Differential usage of
T cell receptor V gene segments in CD4 and CD8 subsets of T lympho-
cytes in monozygotic twins. J. Immunol. 150:2033–2045.
17. Hill, A. V. S. 1998. The immunogenetics of human infectious diseases. Annu.
Rev. Immunol. 16:593–617.
18. Kimura, A., and T. Sasazuki. 1992. Eleventh International Histocompatibil-
ity Workshop reference protocol for the HLA DNA-typing technique, p.
397–419. In K. Tsuji, M. Aizawa, and T. Sasazuki (ed.), HLA 1991. Oxford
Science Publications, London, United Kingdom.
19. Ohmen, J. D., P. F. Barnes, C. L. Grisso, B. R. Bloom, and R. L. Modlin.
1994. Evidence for a superantigen in human tuberculosis. Immunity 1:35–43.
20. Pannetier, C., J. Even, and P. Kourilsky. 1995. T-cell repertoire diversity and
clonal expansions in normal and clinical samples. Immunol. Today 16:176–
181.
21. Pantaleo, G., J. F. Demarest, H. Soudeyns, C. Graziosi, F. Denis, J. W.
Adeisberger, P. Borrow, M. S. Saag, G. M. Shaw, R. P. Sekaly, and A. S.
Fauci. 1994. Major expansion of CD8 T cells with a predominant V-usage
during the primary immune response to HIV. Nature 370:463–467.
21a.Pitchappan, R. M. 2002. Castes, migration, immunogenetics and infectious
diseases in south India. Community Genet. 5:157–161.
22. Pitchappan, R. M., V. Brahmajothi, K. Rajaram, P. T. Subramanyam, K.
Balakrishnan, and R. Muthuveeralakshmi. 1991. Spectrum of immune re-
activity to mycobacterial (BCG) antigens in healthy hospital contacts in
south India. Tubercle 72:133–139.
23. Ramakrishnan, N. S., J. Grunewald, C. H. Janson, and H. Wigzell. 1992.
Nearly identical TCR V gene usage at birth in two cohorts of distinctly
different ethnic origin: influence of environment in the final maturation in
the adult. Scand. J. Immunol. 36:71–78.
24. Ravikumar, M., V. Dheenadhayalan, K. Rajaram, S. Shanmugalakshmi,
P. P. Kumaran, C. N. Paramasivan, K. Balakrishnan, and R. M. Pitchappan.
1999. Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary
tuberculosis in South India. Tuber. Lung Dis. 79:309–317.
25. Roitt, I., J. Brostoff, and D. Male. 1999. Immunology, 5th ed. Harcourt Brace
& Company Asia PTE Ltd., Singapore.
26. Sekaly, R. P. 1998. Measuring reconstitution of the T-cell receptor repertoire
in HIV infection. PRN Notebook 3:17–19.
27. Selvaraj, P., H. Uma, A. M. Reetha, T. Xavier, R. Prabhakar, and P. R.
Narayanan. 1998. Influence of HLA-DR2 phenotype on humoral immunity
and lymphocyte response to Mycobacterium tuberculosis culture filtrate an-
tigens in pulmonary tuberculosis. Indian J. Med. Res. 107:208–217.
28. Silver, J., B. Gulwani-Akolkar, and P. N. Akolkar. 1995. The influence of
genetics, environment and disease state on the human T-cell receptor rep-
ertoire, p. 28–52. In M. M. Davis and J. Buxbaum (ed.), T-cell receptor use
4552 SHANMUGALAKSHMI ET AL. INFECT. IMMUN.
in human autoimmune diseases. The New York Academy of Sciences, New
York, N.Y.
29. Snedecor, G. W., and W. G. Cochran. 1968. Statistical methods, 6th ed.
Oxford & IBH Publishing Co. Pvt. Ltd., New Delhi, India.
30. Soruri, A., S. Schweyer, S., H. J. Radzun, and A. Fayyazi. 2002. Mycobac-
terial antigens induce apoptosis in human purified protein derivative-specific
alphabeta T lymphocytes in a concentration-dependent manner. Immunol-
ogy 105:222–230.
31. Struyk, L., G. E. Hawes, J. B. A. G. Haanen, R. R. de Vries, and P. J. van den
Elsen. 1995. Clonal dominance and selection for similar complementarity
determining region 3 motifs among T lymphocytes responding to the HLA-
DR3-associated Mycobacterium leprae heat shock protein 65-kd peptide
3–13. Hum. Immunol. 44:220–227.
32. Struyk, L., J. T. Kurnick, G. E. Hawes, J. M. van Laar, J. R. Oksenberg, L.
Steinman, L., R. R. P. de Vries, F. C. Breedveld, and P. J. van den Elsen.
1993. T-cell receptor V-gene usage in synovial fluid lymphocytes of patients
with chronic arthritis. Hum. Immunol. 37:237–251.
33. Usuku, K., N. Joshi, C. J. Hatem, M. A. Wong, M. C. Stein, and S. L. Hauser.
1996. Biased expression of T cell receptor genes characterizes activated T
cells in multiple sclerosis cerebrospinal fluid. J. Neurosci. Res. 45:829–837.
34. Wang, X.-H., L. Golkar, K. Uyemura, J. D. Ohmen, L. G. Villahermosa, T. T.
Fajardo, R. V. Cellona, G. P. Walsh, and R. L. Modlin. 1993. T cells bearing
V6 T cell receptors in the cell-mediated immune responses to Mycobacte-
rium leprae. J. Immunol. 151:7105–7116.
35. Wang, X.-H., J. D. Ohmen, K. Uyemura, T. H. Rea, M. Kronenbert, and R. L.
Modlin. 1993. Selection of T lymphocytes bearing limited T-cell receptor 
chains in the response to a human pathogen. Proc. Natl. Acad. Sci. USA
90:188–192.
36. World Health Organization. 1994. TB-a global emergency. WHO report on
the TB epidemic. World Health Organization, Geneva, Switzerland.
37. Wucherpfennig, K. W., and J. L. Strominger. 1995. Molecular mimicry in
T-cell mediated autoimmunity: viral peptides activate human T cell clones
specific for myelin basic protein. Cell 80:695–705.
Editor: S. H. E. Kaufmann
VOL. 71, 2003 TCR V IN PULMONARY TUBERCULOSIS 4553
